MIGS technology remains key driver of glaucoma surgery volume.
Alcon’s reported decline in LenSx sales reflects issues weighing on segment.
The MIGS implant is indicated for refractory glaucoma cases.
The company has raised $740 million through venture capital, public offerings, and licensing deals.
He took the helm in January and said he was involved in finding “the right home” for the unit.
The product will be launched by US-based Sun Ophthalmics, likely before the end of 2016, the company said.
The Schwind family will retain a significant interest, and Rolf Schwind will remain CEO.
Australia-based company plans to increase sales force.
The segment is expected to grow to nearly $4.5 billion by 2021.
One notable finding was participants reported more visual symptoms on the questionnaire than to their health care professionals.
The legislation is designed to speed drug and device approval by the US FDA.
The drugmaker expects a decision in the fourth quarter of 2017.
US retina specialists use Avastin off-label in more than 50 percent of cases of wet AMD, according to Market Scope surveys.
You are not currently logged in.
©2017 Market Scope
Lost your Password